1Weiss LM, Warnke RA, Sklar J, Cleary ML (1987) Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 317: 1185-1189.
2Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, et al. (1998) Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92: 3152-3162.
3Ladanyi M, Offit K, Jhanwar SC, Filippa DA, Chaganti RS (1991) MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. Blood 77: 1057-1063.
4Swerdlow SH, Campo E, Harris NE, et al, (2008) WHO classification of tumours of haematopoietic and lymphoid tissues (4th edn). International Agency for Research on Cancer (IARC) Press
5Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242.
6Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, et al. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the groupe d'etude des lymphomes de l'adulte. J Clin Oncol 23: 4117-4126.
7NCCN clinical practice guidelines in oncology: Non-hodgkin's lymphomas National Comprehensive Cancer Network, Inc; 2011.
8McClure RF, Remstein ED, Macon WR, Dewald GW, Habermann TM, et al. (2005) Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol 29: 1652-1660.
9Macpherson N, Lesack D, Klasa R, Horsman D, Connors JM, et al. (1999) Small noncleaved, non-burkitt's (burkit-like) lymphoma: Cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 17: 1558-1567.
10Anderson J, Armitage JO, Berger F, Cavalli F, Chan WC (1997) A clinical evaluation of the international lymphoma study group classification of non-hodgkin's lymphoma. the non-hodgkin's lymphoma classification project. Blood 89: 3909-3918.
11Dave SS, Fu K, Wright GW, Lam LT, Kluin P, et al. (2006) Molecular diagnosis of burkitt's lymphoma. N Engl J Med 354: 2431-2442.
12Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, et al. (2006) A biologic definition of burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354: 2419-2430.
13 Perry AM, Crockett D, Dave BJ, Althof P, Winkler L, et al. (2013) B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: Study of 39 cases. Br J Haematol 162: 40-49.
14Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, et al. (2009) Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival. Blood 114: 2273-2279.
15Bürgesser MV, Gualco G, Diller A, Natkunam Y, Bacchi CE (2013) Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and burkitt lymphomas: A study of 44 patients from argentina. Ann Diagn Pathol 17: 250-255.
16Nomura Y, Karube K, Suzuki R, Ying G, Takeshita M, et al. (2008) High-grade mature B-cell lymphoma with burkitt-like morphology: Results of a clinicopathological study of 72 japanese patients. Cancer Sci 99: 246-252.
17Corazzelli G, Frigeri F, Russo F, Frairia C, Arcamone M, et al. (2012) RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma. Br J Haematol 156: 234-244.
18Lin P, Dickason TJ, Fayad LE, Lennon PA, Hu P, et al. (2012) Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma. Cancer 118: 1566-1573.
19Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, et al. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586.
20Crump M, Baetz T, Couban S, Belch A, Marcellus D, et al. (2004) Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-hodgkin lymphoma: A phase II study by the national cancer institute of canada clinical trials group (NCIC-CTG). Cancer 101: 1835-1842.
21Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, et al. (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP). Blood 71: 117-122.
22Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, et al. (2006) Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-hodgkin's lymphoma. Cancer Invest 24: 593-600.
23Blum KA, Lozanski G, Byrd JC (2004) Adult burkitt leukemia and lymphoma. Blood 104: 3009-3020.
24Lacasce A, Howard O, Lib S, Fisher D, Weng A, et al. (2004) Modified magrath regimens for adults with burkitt and burkitt-like lymphomas: Preserved efficacy with decreased toxicity. Leuk Lymphoma 45: 761-767.
25Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, et al. ( 2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult burkitt's lymphoma: Results of united kingdom lymphoma group LY06 study. Ann Oncol 13: 1264-1274.
26Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, et al. (1999) Hyper-CVAD program in burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 17: 2461-2470.
27Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, et al. (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult burkitt and burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106: 1569-1580.
28Segal GH, Jorgensen T, Scott M, Braylan RC (1994) Optimal primer selection for clonality assessment by polymerase chain reaction analysis: II. follicular lymphomas. Hum Pathol 25: 1276-1282.
29Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, et al. (2007) The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 92: 1335-1342.
30Kanungo A, Medeiros LJ, Abruzzo LV, Lin P (2006) Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 19: 25-33.
31Niitsu N, Okamoto M, Miura I, Hirano M (2009) Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 23: 777-783.
32Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, et al. (2010) B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 34: 327-340.
33Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, et al. (2011) Double-hit B-cell lymphomas. Blood 117: 2319-2331.
34Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, et al. (2012) B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): An aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 25:145-56.
35Mohamed AN, Palutke M, Eisenberg L, Al-Katib A (2001) Chromosomal analyses of 52 cases of follicular lymphoma with t(14;18), including blastic/blastoid variant. Cancer Genet Cytogenet 126: 45-51.
36Christie L, Kernohan N, Levison D, Sales M, Cunningham J, et al. (2008) C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator? Leuk Lymphoma 49: 470-476.